Table 1

Overall incidence of aberrancies in common T-cell markers in tumor cells of MF and SS.

Aberrancy

CD3

CD4

CD5*

CD7

CD8

CD26

CD45*

TCR*


% of cases

34%

54%

25%

61%

5%

86%

40%

31%

cases tested

15/44

24/44

5/20

27/44

2/44

38/44

4/10

6/19


*Markers tested on only a subset of cases.

Washington et al. BMC Clinical Pathology 2002 2:5   doi:10.1186/1472-6890-2-5

Open Data